Drug Trial Radar · NCT04616560
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Mar 8, 2021
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Nov 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 39 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial studies the effects of trastuzumab deruxtecan (DS-8201a) in treating patients with osteosarcoma, Wilms tumor (WT) or desmoplastic small round cell tumor (DSRCT) that is newly diagnosed or has come back after a period of improvement (recurrent) or that has not responded to previous treatment (refractory). Trastuzumab deruxtecan is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them.
Conditions
- Desmoplastic Small Round Cell Tumor
- Osteosarcoma
- Recurrent Desmoplastic Small Round Cell Tumor
- Recurrent Kidney Wilms Tumor
- Recurrent Osteosarcoma
- Refractory Desmoplastic Small Round Cell Tumor
- Refractory Wilms Tumor
- Wilms Tumor
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo CT
Echocardiography TestProcedure
Undergo echocardiography
Magnetic Resonance ImagingProcedure
Undergo MRI
Multigated Acquisition ScanProcedure
Undergo MUGA
Trastuzumab DeruxtecanBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose and/or recommended phase 2 dose of DS-8201a in children at least 2 to less than 12 years old with recurrent or refractory Wilms tumor (WT) or desmoplastic small round cell tumor (DSRCT) (Phase 1)Time frame: During the first cycle of therapy (cycle length = 21 days)
- Incidence of adverse events (AEs) in children at least 2 to less than 12 years old with recurrent or refractory WT or DSRCT (Phase 1)Time frame: Up to 30 days after last dose of study treatment
- Time to progressionTime frame: Up to 1 year
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama · Suspended
Children's Hospital Los Angeles
Los Angeles, California · Recruiting
Children's Hospital of Orange County
Orange, California · Suspended
Lucile Packard Children's Hospital Stanford University
Palo Alto, California · Recruiting
UCSF Medical Center-Mission Bay
San Francisco, California · Suspended
Children's Hospital Colorado
Aurora, Colorado · Suspended
Children's National Medical Center
Washington D.C., District of Columbia · Recruiting
Johns Hopkins All Children's Hospital
St. Petersburg, Florida · Recruiting
Children's Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, Georgia · Recruiting
Lurie Children's Hospital-Chicago
Chicago, Illinois · Suspended
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Recruiting
Riley Hospital for Children
Indianapolis, Indiana · Suspended
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
C S Mott Children's Hospital
Ann Arbor, Michigan · Recruiting
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota · Suspended
Children's Mercy Hospitals and Clinics
Kansas City, Missouri · Suspended
Washington University School of Medicine
St Louis, Missouri · Recruiting
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
New York Medical College
Valhalla, New York · Recruiting
Duke University Medical Center
Durham, North Carolina · Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania · Suspended
Saint Jude Children's Research Hospital
Memphis, Tennessee · Recruiting
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee · Active not recruiting
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas · Recruiting
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas · Recruiting
Primary Children's Hospital
Salt Lake City, Utah · Suspended
Seattle Children's Hospital
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.